Fengate Buys Majority Stake in Clinical Research West Florida

Toronto-based Fengate Private Equity has acquired a majority stake in a Tampa Bay clinical research company that runs three facilities in Clearwater and Tampa.

Updated on Nov. 2, 2026 in Healthcare

Fengate Buys Majority Stake in Clinical Research West Florida

Live Poll

Do you trust private equity firms to improve local healthcare providers?

Fengate Private Equity, a division of Toronto-based Fengate Asset Management, has acquired a majority stake in Clinical Research of West Florida, a Tampa Bay-area company that operates three research facilities in Clearwater and Tampa. Financial terms of the deal were not disclosed.

Why it matters

The acquisition adds a clinical research operator with a 30-year history to a growing set of pharma services investments made by Fengate on behalf of the LiUNA Pension Fund of Central and Eastern Canada. For Clearwater residents and the region's healthcare sector, it signals continued investment in local clinical trial infrastructure.

Clinical Research of West Florida reports more than 1,000 supported trials, over 12,000 screened patients, and work with nearly 300 biopharmaceutical sponsors and contract research organizations. The announcement did not disclose the acquisition's financial terms.

The players

Fengate Private Equity

Fengate Private Equity is a division of Toronto-based Fengate Asset Management that invests in lower middle-market businesses across North America and, with this deal, made its second pharma services platform investment.

Clinical Research of West Florida

Clinical Research of West Florida is a Tampa Bay-area clinical research organization operating three facilities in Clearwater and Tampa.

The details

Fengate Private Equity manages the investment on behalf of the LiUNA Pension Fund of Central and Eastern Canada. The organization plans to keep investing in capabilities and infrastructure, and Clinical Research of West Florida plans to develop new sites and partner with independent research sites across the southeast.

November 2, 2026: Article published announcing the acquisition.

Market Landscape

This is Fengate's second pharma services platform investment, extending a strategy built around lower middle-market healthcare services businesses across North America. The move places a Tampa Bay clinical research operator inside a portfolio pursuing regional expansion in the Southeast.

Patients in the Clearwater and Tampa area may see expanded access to clinical trial opportunities if Clinical Research of West Florida follows through on its plans to add new sites and partner with independent research sites across the southeast. The company has screened more than 12,000 patients to date, which indicates a substantial local pool of trial participants.

The takeaway

The deal reflects private equity interest in regional clinical research infrastructure, which may shape how and where future trials are run in Florida's Tampa Bay area. Residents interested in trial participation can watch for new site openings as the company's expansion plans take shape.